

RESEARCH MONOGRAPH . COMPOUND PROFILE

Pelacarsen

A hepatocyte-directed, triantennary N-acetylgalactosamine-conjugated antisense oligonucleotide developed by Ionis Pharmaceuticals and licensed to Novartis, designed to selectively reduce circulating lipoprotein(a) concentrations by RNase H1-mediated degradation of apolipoprotein(a) mRNA in hepatocytes, currently under evaluation in the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial.

DOCUMENT	KDC-MN-1625
ISSUED	2026-05-21
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	GalNAc3-conjugated 2'-MOE antisense oligonucleotide targeting apolipoprotein(a) mRNA for lipoprotein(a) reduction

ABSTRACT

Pelacarsen (ISIS 681257; also designated IONIS-APO(a)-LRx, AKCEA-APO(a)-LRx, and TQJ230) is a second-generation, hepatocyte-directed antisense oligonucleotide (ASO) conjugated to a triantennary N-acetylgalactosamine (GalNAc3) ligand, designed to reduce circulating lipoprotein(a) [Lp(a)] concentrations by selective inhibition of apolipoprotein(a) [apo(a)] synthesis in the liver. The compound targets the messenger RNA transcribed from the LPA gene, binding with high specificity and triggering RNase H1-mediated cleavage and subsequent degradation of the transcript, thereby preventing translation of the apo(a) protein that is the defining structural component of the Lp(a) particle. The GalNAc3 conjugation exploits the high-density expression of the asialoglycoprotein receptor (ASGPR) on hepatocyte surfaces to achieve rapid, selective uptake into the liver, the exclusive site of apo(a) biosynthesis, conferring a 20- to 30-fold improvement in potency relative to the unconjugated parent compound IONIS-APO(a)Rx and enabling clinically effective Lp(a) lowering at substantially reduced doses and extended dosing intervals.

Lipoprotein(a) is a genetically determined, independent, and causal risk factor for atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve stenosis (CAVS), and thrombotic events. Plasma Lp(a) concentrations are primarily determined by LPA gene variation and are minimally responsive to lifestyle modification or conventional lipid-lowering pharmacotherapy including statins, ezetimibe, and PCSK9 inhibitors. Approximately 20 to 25 percent of the global population carries Lp(a)

concentrations above 50 mg/dL, the threshold at which epidemiological and Mendelian randomization data consistently demonstrate elevated cardiovascular risk. Prior to the development of targeted Lp(a)-lowering agents, no pharmacotherapy had demonstrated selective, potent, and sustained reduction of Lp(a) in a manner suitable for chronic cardiovascular risk management.

In the pivotal Phase 2b dose-ranging trial (Tsimikas et al., 2020, New England Journal of Medicine), pelacarsen administered subcutaneously to 286 patients with established ASCVD and Lp(a) concentrations of 60 mg/dL or greater produced dose-dependent Lp(a) reductions of 35 to 80 percent across five dosing regimens (20 mg every 4 weeks, 40 mg every 4 weeks, 60 mg every 4 weeks, 20 mg every 2 weeks, and 20 mg every week) over 6 to 12 months, with the 20 mg weekly regimen achieving approximately 80 percent mean reduction. The compound was well tolerated; the principal adverse events were mild injection site reactions. On the basis of these results, the 80 mg monthly subcutaneous dose was selected for the Phase 3 cardiovascular outcomes program.

The Lp(a)HORIZON trial (NCT04023552) is a randomized, double-blind, placebo-controlled Phase 3 study enrolling 8,323 patients with established cardiovascular disease and Lp(a) concentrations of 70 mg/dL or greater, designed to evaluate whether pelacarsen 80 mg administered subcutaneously once monthly reduces the incidence of major adverse cardiovascular events (MACE; composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization) relative to placebo on a background of optimized standard-of-care therapy. Enrollment was completed in 2022; topline results are anticipated in 2026. A companion Phase

3 trial (Lp(a)FRONTIERS CAVS) evaluates pelacarsen in calcific aortic valve stenosis progression. This monograph reviews the chemistry, conjugation technology, and molecular pharmacology of pelacarsen; the comprehensive pharmacokinetic record including hepatic impairment and ethnic pharmacokinetic data; the preclinical and clinical evidence base; sourcing and handling considerations; stack interactions; adverse events and safety signal; and a comparative assessment of five Lp(a)-lowering agents against pelacarsen on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Pelacarsen.

Development codes: ISIS 681257 (Ionis Pharmaceuticals internal designation), IONIS-APO(a)-LRx (Ionis ligand-conjugated antisense program designation), AKCEA-APO(a)-LRx (Akcea Therapeutics designation, reflecting the Ionis subsidiary that initially managed commercial development), TQJ230 (Novartis development code assigned following the 2019 licensing agreement). The Ionis designations are canonical in the early pharmacology and Phase 1 literature; the TQJ230 code is the identifier in the Phase 3 Lp(a)HORIZON clinical trial registry and in Novartis regulatory filings [1, 2].

Chemical Abstracts Service registry number: 1637637-70-7.

Molecular formula: C₂₉₆H₄₃₉N₇₁O₁₆₃P₂₀S₁₃.

Molecular weight: 8636.36 g/mol.

Drug class: Antisense oligonucleotide (ASO), GalNAc3-conjugated, 2'-O-methoxyethyl (2'-MOE) modified, phosphorothioate backbone.

1.2 Structural class and chemistry

Pelacarsen is a synthetic single-stranded oligonucleotide of 20 nucleotides in length, designed to hybridize with a complementary sequence in the mRNA transcribed from the human LPA gene encoding apolipoprotein(a). The oligonucleotide backbone incorporates phosphorothioate (PS) internucleotide linkages throughout, replacing the native phosphodiester bonds to confer resistance to nuclease degradation and to enhance binding to plasma proteins for improved tissue distribution. The flanking nucleotides (positions 1 through 5 and 16 through 20) carry 2'-O-methoxyethyl (2'-MOE) sugar modifications, forming a gapmer architecture in which the central deoxynucleotide gap (positions 6 through 15) supports RNase H1 recognition and cleavage of the target mRNA duplex, while the MOE-modified flanks enhance binding affinity and further increase nuclease resistance [3, 4].

The compound is covalently conjugated at its 5' terminus to a triantennary N-acetylgalactosamine (GalNAc3) cluster through a tether-linker chemistry. The GalNAc3 ligand is a synthetic trisaccharide that binds with high affinity to the asialoglycoprotein receptor (ASGPR), a C-type lectin expressed at high density (approximately 500,000 copies per cell) on the sinusoidal surface of hepatocytes. ASGPR-mediated endocytosis delivers the conjugate into the hepatocyte endosomal and lysosomal compartments, from which the oligonucleotide escapes to the cytoplasm and nucleus to engage its mRNA target. This ligand-conjugated antisense (LICA) technology, developed by Ionis Pharmaceuticals, confers a 20- to 30-fold improvement in hepatic potency relative to unconjugated ASOs of identical sequence, enabling effective target knockdown at substantially lower doses and extended dosing intervals [3, 5].

Physical properties: Pelacarsen is supplied as a clear to slightly opalescent, colorless to pale yellow solution for subcutaneous injection. The compound is water-soluble as formulated. The large molecular weight (8.6 kDa) and polyanionic character of the phosphorothioate backbone confer high plasma protein binding (greater than 95 percent, predominantly to albumin) and substantial tissue distribution.

1.3 Synthesis

The synthesis of pelacarsen proceeds by automated solid-phase oligonucleotide synthesis using phosphoramidite chemistry on controlled-pore glass supports. The 20-mer oligonucleotide is assembled in the 3' to 5' direction by sequential coupling of protected 2'-MOE phosphoramidite monomers (for the flanking positions) and 2'-deoxyphosphoramidite monomers (for the central gap positions), with sulfurization of the phosphite triester intermediates to generate the phosphorothioate linkages. Following chain assembly and global deprotection, the GalNAc3 cluster is conjugated at the 5' terminus through post-synthetic coupling chemistry. The crude product is purified by anion-exchange chromatography and/or reversed-phase high-performance liquid chromatography, desalted, and formulated in an aqueous buffer for subcutaneous injection. Quality control includes oligonucleotide identity confirmation by mass spectrometry, purity assessment by capillary electrophoresis and HPLC, sequence confirmation, residual solvent analysis, endotoxin testing, and sterility testing. The manufacturing process is conducted under current Good Manufacturing Practice (cGMP) conditions at Ionis-affiliated or contract manufacturing facilities [3].

2. Abstract

Pelacarsen (ISIS 681257, TQJ230) is a GalNAc3-conjugated 2'-MOE gapmer antisense oligonucleotide that selectively inhibits hepatic synthesis of apolipoprotein(a), the defining protein component of the lipoprotein(a) [Lp(a)] particle, by RNase H1-mediated degradation of LPA mRNA [1, 3]. The compound represents the most clinically advanced targeted Lp(a)-lowering agent, having completed Phase 2b dose-ranging evaluation in patients with established atherosclerotic cardiovascular disease and currently under evaluation in the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial (NCT04023552; 8,323 patients) and the Phase 3 Lp(a)FRONTIERS CAVS trial for calcific aortic valve stenosis [2, 6].

Lipoprotein(a) is a genetically determined lipoprotein particle consisting of a low-density lipoprotein (LDL)-like core with a single apolipoprotein B-100 molecule covalently linked by a disulfide bond to a single molecule of apolipoprotein(a), a large, highly polymorphic glycoprotein encoded by the LPA gene. Lp(a) concentrations are approximately 90 percent heritable, are resistant to modification by diet, exercise, or standard lipid-lowering therapy, and are an established independent and causal risk factor for myocardial infarction, stroke, peripheral arterial disease, calcific aortic valve stenosis, and heart failure [7, 8]. Mendelian randomization studies have consistently demonstrated that genetically elevated Lp(a) is associated with proportionally increased cardiovascular event rates, and that the magnitude of risk reduction expected from Lp(a) lowering is approximately 3 to 4 percent per 10 mg/dL absolute reduction [9].

In the Phase 2b trial published by Tsimikas et al. (2020), pelacarsen produced dose-dependent Lp(a) reductions of 35 to 80 percent across five subcutaneous dosing regimens in 286 patients with established ASCVD and baseline Lp(a) of 60 mg/dL or greater, with 98 percent of participants in the highest-dose group achieving Lp(a) below 50 mg/dL [1]. The compound was well tolerated; the principal adverse events were mild, self-limiting injection site reactions. Pharmacokinetic characterization demonstrates a prolonged elimination half-life of approximately 21 to 22 days following subcutaneous administration, supporting once-monthly dosing at the 80 mg dose selected for Phase 3 evaluation [10]. Pelacarsen is devel-

oped by Ionis Pharmaceuticals and licensed to Novartis for global development and commercialization under a 2019 agreement valued at \$150 million in upfront payment [2].

3. Discovery and Development History

3.1 Origin and rationale

The development of pelacarsen originates from the convergence of two scientific streams: the decades-long epidemiological and genetic characterization of lipoprotein(a) as an independent cardiovascular risk factor, and the maturation of antisense oligonucleotide technology at Ionis Pharmaceuticals (formerly ISIS Pharmaceuticals) as a platform for targeted gene silencing in hepatocytes [3, 7].

The causal relationship between elevated Lp(a) and cardiovascular disease was established through large-scale prospective cohort studies (the Copenhagen City Heart Study, the Emerging Risk Factors Collaboration) and through Mendelian randomization analyses demonstrating that LPA gene variants associated with elevated Lp(a) concentrations are proportionally associated with increased risk of coronary heart disease, ischemic stroke, and calcific aortic valve stenosis [7, 8, 9]. The absence of effective pharmacotherapy for Lp(a) lowering (statins are Lp(a)-neutral or modestly increase Lp(a); niacin reduces Lp(a) by approximately 20 to 30 percent but failed to demonstrate cardiovascular benefit in the AIM-HIGH and HPS2-THRIVE outcomes trials) created a substantial therapeutic gap [11, 12].

3.2 First-generation compound: IONIS-APO(a)Rx

Ionis Pharmaceuticals developed a first-generation unconjugated 2'-MOE antisense oligonucleotide targeting LPA mRNA, designated IONIS-APO(a)Rx (ISIS 494372). In Phase 1 clinical evaluation, IONIS-APO(a)Rx administered subcutaneously at doses of 100 to 300 mg produced Lp(a) reductions of up to 77.8 percent in healthy volunteers with elevated Lp(a), with the nadir occurring approximately 36 days after the last dose [13]. While demonstrating proof of concept for the antisense approach to Lp(a) lowering, the unconjugated compound required relatively high doses (100 to 300 mg) and frequent dosing to achieve meaningful target knockdown, presenting practical limitations for chronic cardiovascular risk management.

3.3 Second-generation compound: pelacarsen

The application of Ionis' Ligand-Conjugated Antisense (LICA) technology, specifically GalNAc3 conjugation, to the APO(a) antisense sequence produced pelacarsen (ISIS 681257, IONIS-APO(a)-LRx). The GalNAc3 conjugate demonstrated a 20- to 30-fold improvement in potency for hepatic Lp(a) mRNA knockdown relative to the unconjugated parent compound, enabling effective Lp(a) lowering at doses of 20 to 80 mg with monthly or less frequent dosing intervals [3, 5]. The improvement was attributable to the high-efficiency, ASGPR-mediated hepatocyte uptake pathway that concentrates the oligonucleotide at its site of action. The GalNAc-conjugated compound entered clinical development in approximately 2015.

3.4 Clinical development timeline

Phase 1 healthy volunteer studies (NCT02414594) established the safety, pharmacokinetic profile, and dose-dependent pharmacodynamic activity of pelacarsen. The Phase 2b dose-ranging trial, reported by Tsimikas et al. in the New England Journal of Medicine in 2020, enrolled 286 patients with established cardiovascular disease and Lp(a) of 60 mg/dL or greater and demonstrated 35 to 80 percent Lp(a) reduction across five dosing regimens [1]. In 2017, Novartis entered a collaboration agreement with Ionis Pharmaceuticals for pelacarsen development. In February 2019, Novartis exercised an option to license exclusive worldwide rights to develop and commercialize pelacarsen, paying \$150 million upfront [2]. The Phase 3 Lp(a)HORIZON cardiovascular outcomes trial (NCT04023552) began enrollment in 2019, achieved 50 percent enrollment in 2021, and completed full enrollment of 8,323 patients in 2022. Topline results are anticipated in 2026 [6, 14]. Additional Phase 3 trials include the Lp(a)FRONTIERS CAVS trial for calcific aortic valve stenosis and a Phase 3b trial (NCT06267560) evaluating pelacarsen in Black/African American and Hispanic participants with ASCVD and elevated Lp(a).

4. Molecular Pharmacology

4.1 Target: LPA mRNA and apolipoprotein(a) biosynthesis

The pharmacological target of pelacarsen is the mRNA transcribed from the LPA gene, which encodes apolipoprotein(a) [apo(a)]. The LPA gene is located on chromosome 6q25.3 and is expressed exclusively in hepatocytes. Apo(a) is a large, highly polymorphic glycoprotein characterized by multiple kringle domains (kringle IV types 1 through 10, with type 2 present in a variable number of tandemly repeated copies ranging from 2 to greater than 40, and a single kringle V domain) and an inactive protease-like domain. Following hepatic synthesis and secretion, apo(a) assembles with apolipoprotein B-100 on LDL-like particles in the plasma through a disulfide bond between kringle IV type 9 of apo(a) and a cysteine residue on apoB-100, forming the mature Lp(a) particle [7, 8].

The number of kringle IV type 2 repeats (the KIV-2 copy number variation) is the principal genetic determinant of Lp(a) concentration: smaller apo(a) isoforms (fewer KIV-2 repeats) are secreted more efficiently from hepatocytes and are associated with higher plasma Lp(a) concentrations, while larger isoforms (more repeats) are retained intracellularly and are associated with lower concentrations. Pelacarsen targets the LPA mRNA at a conserved sequence region, and its mechanism of action is independent of isoform size, reducing apo(a) synthesis regardless of the KIV-2 copy number [1, 3].

4.2 Mechanism: RNase H1-mediated mRNA degradation

Pelacarsen operates through the canonical antisense mechanism for gapmer oligonucleotides. Following ASGPR-mediated endocytosis into hepatocytes, the oligonucleotide escapes from the endosomal compartment to the cytoplasm and nucleus, where it hybridizes with its complementary sequence on the LPA mRNA by Watson-Crick base pairing. The central deoxynucleotide gap of the gapmer (positions 6 through 15) forms a DNA:RNA heteroduplex with the target mRNA, which is recognized and cleaved by RNase H1, an endogenous endonuclease that selectively degrades the RNA strand of DNA:RNA duplexes. The cleaved mRNA fragments are subsequently degraded by cellular exonucleases, and the intact pelacarsen oligonu-

cleotide is recycled to engage additional mRNA molecules. This catalytic mechanism contributes to the prolonged pharmacodynamic effect and enables sustained Lp(a) lowering with monthly dosing [3, 4, 5].

The specificity of the antisense mechanism is determined by the 20-nucleotide complementary sequence, which is designed to be unique to the LPA transcript and to lack significant homology with other human mRNAs. The LPA gene is paralogous to the plasminogen (PLG) gene; the pelacarsen sequence was selected to target a region of the LPA mRNA that is sufficiently divergent from PLG mRNA to avoid cross-hybridization and plasminogen knockdown [3].

4.3 GalNAc3 conjugation and hepatocyte targeting

The triantennary GalNAc3 cluster at the 5' terminus of pelacarsen binds to the asialoglycoprotein receptor (ASGPR), a calcium-dependent C-type lectin heterodimer (H1/H2 subunits) expressed at high density on the basolateral (sinusoidal) surface of hepatocytes. ASGPR undergoes constitutive endocytosis with a recycling half-life of approximately 15 minutes, mediating rapid internalization of GalNAc-conjugated ligands. Following receptor-mediated endocytosis, the conjugate is delivered to early endosomes, where the acidic pH promotes dissociation of the ligand from the receptor. The receptor recycles to the cell surface, while the oligonucleotide traffics through the endolysosomal pathway. A small but pharmacologically sufficient fraction of the internalized oligonucleotide escapes from endosomes to the cytoplasm, where it engages its mRNA target [3, 5].

The hepatocyte-directed delivery mechanism is the principal pharmacological advantage of pelacarsen over unconjugated ASOs. By concentrating the oligonucleotide in hepatocytes (the exclusive site of apo(a) synthesis), GalNAc3 conjugation reduces the dose required for effective target knockdown by 20- to 30-fold and correspondingly reduces exposure of non-hepatic tissues, potentially improving the therapeutic index [5].

4.4 Downstream pharmacodynamic effects

The primary pharmacodynamic consequence of pelacarsen-mediated apo(a) mRNA degradation is reduction of circulating Lp(a) particle concentration. Because apo(a) is the obligate structural component of Lp(a), reduction of apo(a) synthesis directly reduces Lp(a) particle assembly and secretion. The Lp(a) reduction is dose-depen-

dent and sustained, with a pharmacodynamic half-life substantially longer than the pharmacokinetic half-life of the oligonucleotide in plasma, reflecting the intracellular accumulation of active oligonucleotide in hepatocytes and its catalytic mechanism of action [1, 10].

Secondary pharmacodynamic effects include reduction of Lp(a)-associated cholesterol (a component of total LDL cholesterol as measured by standard clinical assays) and reduction of Lp(a)-associated oxidized phospholipids (OxPL), which are pro-inflammatory and pro-thrombotic mediators carried on the Lp(a) particle. In the Phase 2b trial, pelacarsen reduced Lp(a)-cholesterol by a magnitude corresponding to the Lp(a) particle reduction, with a consequent reduction in the calculated "corrected" LDL cholesterol (LDL-c minus Lp(a)-cholesterol) [1, 15]. The reduction of OxPL-apo(a) and OxPL-apoB is a distinctive anti-inflammatory mechanism that differentiates Lp(a) lowering from conventional LDL cholesterol lowering.

5. Pharmacokinetics

5.1 Absorption

Pelacarsen is administered by subcutaneous injection. Following a single 80 mg subcutaneous dose, the compound is absorbed from the injection site into the systemic circulation with a median time to peak plasma concentration (T_{max}) of approximately 1.5 to 2.0 hours. Approximately 83 to 88 percent of the total plasma exposure (AUC) occurs within the first 24 hours post-dose, reflecting the rapid absorption phase followed by distribution into tissues [10, 16].

Oral bioavailability of antisense oligonucleotides is negligible owing to degradation in the gastrointestinal tract and poor permeability across intestinal epithelium; subcutaneous injection is the only clinically viable route for pelacarsen.

5.2 Distribution

Pelacarsen has a large apparent volume of distribution (V_z/F approximately 7,300 to 8,400 liters in healthy subjects), reflecting extensive tissue distribution characteristic of phosphorothioate antisense oligonucleotides. Plasma protein binding exceeds 95 percent, predominantly to albumin, with the polyanionic phosphorothioate backbone driving non-specific electrostatic interactions with cationic protein surfaces. The high protein binding serves as a circulating depot, prolonging plasma residence time and facilitating tissue uptake [10, 16].

The primary site of tissue accumulation is the liver, driven by ASGPR-mediated hepatocyte uptake of the GalNAc3 conjugate. Secondary tissue distribution includes kidney (proximal tubular epithelium, a general feature of phosphorothioate ASOs) and, to a lesser extent, lymph nodes and spleen. Central nervous system penetration is negligible; the compound does not cross the blood-brain barrier at pharmacologically meaningful concentrations [3].

5.3 Metabolism

Pelacarsen is not metabolized by cytochrome P450 enzymes or other phase I or phase II drug-metabolizing enzymes. The principal metabolic pathway is endonuclease-mediated cleavage within tissues, producing shorter oligonucleotide fragments that are further degraded by exonucleases to individual nucleotides. The 2'-MOE and phosphorothioate modifications confer substantial resistance to nuclease degradation, resulting in a prolonged intracellular half-life that supports the extended dosing interval [3, 4].

The GalNAc3 ligand is cleaved from the oligonucleotide within the endolysosomal pathway following ASGPR-mediated uptake; the liberated GalNAc monosaccharides enter normal carbohydrate metabolism and are not pharmacologically active [5].

5.4 Elimination

The elimination half-life of pelacarsen from plasma following a single 80 mg subcutaneous dose is approximately 518 to 533 hours (21 to 22 days), supporting once-monthly dosing [10]. Renal excretion of intact oligonucleotide is minimal; the primary elimination pathway is intracellular nuclease-mediated degradation in liver and kidney, with the resulting short oligonucleotide fragments and nucleotides cleared by renal excretion.

Clearance (CL/F) is approximately 10.2 L/h in subjects with normal hepatic function. Between-participant pharmacokinetic variability is substantial (coefficient of variation 50 to 89 percent for key parameters), a general feature of subcutaneously administered ASOs reflecting variability in injection site absorption, tissue distribution, and intracellular processing [10, 16].

5.5 Special populations

Hepatic impairment: A dedicated pharmacokinetic study in subjects with mild hepatic impairment (Child-Pugh Class A, score 5 to 6) compared to healthy matched controls demonstrated that a single 80 mg subcutaneous dose produced a 7 percent increase in C_{max} and a 37 to 50 percent increase in AUC in the mild hepatic impairment group, attributable to slower early-phase disposition rather than impaired elimination [10]. No dose adjustment is recommended for mild hepatic impairment. Moderate and severe hepatic impairment have not been formally evaluated.

Renal impairment: Dedicated renal impairment pharmacokinetic data have not been published for pelacarsen. Class experience with phosphorothioate ASOs suggests minimal effect of mild to moderate renal impairment on pharmacokinetics, given the predominantly metabolic (nuclease-mediated) elimination pathway. Severe renal impairment and dialysis have not been evaluated.

Ethnic pharmacokinetics: A Phase 1 study in healthy Japanese subjects (NCT05337878) demonstrated dose-dependent Lp(a) reductions of 55.4 to 73.7 percent across 20 to 80 mg single doses by day 30, with pharmacokinetic parameters and safety profile consistent with data from non-Japanese populations [16].

5.6 Routes of administration

Pelacarsen is administered exclusively by subcutaneous injection. The Phase 3 formulation is an 80 mg dose in a prefilled syringe or autoinjector for self-administration by the patient or caregiver following appropriate training. The injection is administered once monthly (every 4 weeks). Common injection sites include the abdomen, thigh, and upper arm [6].

6. Preclinical Pharmacology

6.1 In vitro activity

Pelacarsen demonstrates potent and selective inhibition of LPA mRNA expression in primary human hepatocytes in vitro. The IC₅₀ for LPA mRNA knockdown in cultured hepatocytes is in the low nanomolar range when delivered in the GalNAc3-conjugated form, consistent with the high-efficiency ASGPR-mediated uptake pathway. Selectivity over PLG (plasminogen) mRNA is maintained at pharmacologically relevant concentrations, confirming the sequence-specific antisense mechanism [3].

6.2 In vivo pharmacology

Preclinical evaluation of pelacarsen was conducted in transgenic mice expressing the human LPA gene and in non-human primates. In LPA-transgenic mice, subcutaneous administration of pelacarsen produced dose-dependent reductions in circulating human apo(a) and Lp(a), with the GalNAc3-conjugated compound demonstrating approximately 20-fold greater potency than the unconjugated parent compound at equivalent molar doses. The duration of pharmacodynamic effect was prolonged relative to the plasma elimination, reflecting intracellular oligonucleotide accumulation in hepatocytes [3, 5].

In cynomolgus monkeys, repeated subcutaneous dosing produced sustained Lp(a) reduction with no evidence of hepatotoxicity, nephrotoxicity, or clinically significant hematological effects at multiples of the anticipated human dose. The non-human primate studies informed dose selection and the safety margin for the Phase 1 healthy volunteer program [3].

6.3 Safety pharmacology

Preclinical safety pharmacology studies evaluated cardiovascular (hERG channel, telemetered animal), respiratory, and central nervous system endpoints. No clinically significant effects on QT interval, respiratory function, or neurobehavioral parameters were observed at exposures exceeding the anticipated human therapeutic

range. The phosphorothioate ASO class is associated with a recognized preclinical toxicity profile including complement activation (at high intravenous doses, not observed at subcutaneous therapeutic doses), pro-inflammatory effects at supratherapeutic concentrations, and proximal tubular kidney effects at high chronic doses. The GalNAc3 conjugation reduces systemic exposure and non-hepatic tissue accumulation, potentially mitigating these class-related toxicities [3, 4].

7. Clinical Evidence Base

7.1 Phase 1 studies

The first-in-human Phase 1 study of the unconjugated parent compound IONIS-APO(a)Rx (ISIS 494372) in healthy volunteers with Lp(a) greater than 100 mg/L demonstrated proof-of-concept Lp(a) reduction of up to 77.8 percent with single or multiple subcutaneous injections at doses of 100 to 300 mg. The Lp(a) nadir occurred approximately 36 days after the last dose. Adverse events were mild and included influenza-like reactions and injection site reactions [13].

The Phase 1 study of pelacarsen (the GalNAc3-conjugated compound, NCT02414594) in healthy volunteers with elevated Lp(a) established the safety, pharmacokinetic, and pharmacodynamic profile at doses substantially lower than those required for the unconjugated compound, confirming the 20- to 30-fold potency enhancement conferred by GalNAc3 conjugation [3, 16].

7.2 Phase 2b dose-ranging trial

The pivotal Phase 2b trial (Tsimikas et al., 2020) was a randomized, double-blind, placebo-controlled, dose-ranging study enrolling 286 patients with established cardiovascular disease (history of myocardial infarction, ischemic stroke, or symptomatic peripheral arterial disease) and screening Lp(a) concentration of 60 mg/dL or greater. Patients were randomized to one of five pelacarsen dosing regimens or placebo, administered subcutaneously for 6 to 12 months [1]:

- 20 mg every 4 weeks: mean Lp(a) reduction approximately 35 percent
- 40 mg every 4 weeks: mean Lp(a) reduction approximately 56 percent
- 60 mg every 4 weeks: mean Lp(a) reduction approximately 72 percent
- 20 mg every 2 weeks: mean Lp(a) reduction approximately 58 percent
- 20 mg every week: mean Lp(a) reduction approximately 80 percent

In the 20 mg weekly group, 98 percent of participants achieved Lp(a) concentrations below 50 mg/dL (the threshold associated with lower cardiovascular risk). The Lp(a) reduction was accompanied by a concomitant reduction in Lp(a)-associated

cholesterol and oxidized phospholipids [1, 15].

The compound was well tolerated across all dosing regimens. The most common adverse events were injection site reactions (erythema and pain at the injection site), reported in approximately 27 percent of the highest-dose group; these were predominantly mild and self-limiting. There were no clinically significant effects on liver transaminases, platelet counts, renal function, or hepatic steatosis markers. No serious adverse events were attributed to pelacarsen [1].

7.3 Phase 3 cardiovascular outcomes trial: Lp(a)HORIZON

The Lp(a)HORIZON trial (NCT04023552) is the registration-enabling Phase 3 study. It is a randomized, double-blind, placebo-controlled, event-driven trial enrolling 8,323 patients aged 18 to 80 years with established cardiovascular disease and Lp(a) of 70 mg/dL or greater. Patients are randomized 1:1 to receive pelacarsen 80 mg or matching placebo by subcutaneous injection once monthly on a background of optimized standard-of-care therapy for cardiovascular disease (including statins, antiplatelet agents, and antihypertensives as indicated) [6, 14].

The primary endpoint is the time to first occurrence of a composite of major adverse cardiovascular events: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization. The trial is event-driven, requiring accumulation of 993 adjudicated primary endpoint events. Minimum follow-up is 2.5 years. Enrollment began in 2019 and was completed in 2022. Topline results are anticipated in 2026 [6, 14].

The trial design reflects the Mendelian randomization evidence suggesting that large absolute reductions in Lp(a) (on the order of 65 to 100 mg/dL) are required to produce clinically detectable cardiovascular risk reduction [9]. The 80 mg monthly dose was selected on the basis of the Phase 2b data demonstrating approximately 80 percent Lp(a) reduction, which in patients with baseline Lp(a) of 70 mg/dL or greater would produce absolute reductions in the range expected to confer cardiovascular benefit.

7.4 Additional Phase 3 trials

Lp(a)FRONTIERS CAVS: This Phase 3 trial evaluates the effect of pelacarsen on the progression of calcific aortic valve stenosis, a condition for which elevated Lp(a) is an established causal risk factor through Mendelian randomization analysis. The

trial assesses valve calcification progression by computed tomography and echocardiographic endpoints [6].

Lp(a)FRONTIERS APHERESIS (NCT05305664): A multicenter trial assessing whether pelacarsen can reduce the frequency of lipoprotein apheresis sessions in patients with hyperlipoproteinemia(a) and established cardiovascular disease in Germany, where lipoprotein apheresis is a reimbursed therapy for refractory elevated Lp(a) [17].

Phase 3b diversity trial (NCT06267560): A randomized, double-blind, placebo-controlled trial evaluating pelacarsen 80 mg monthly in Black/African American and Hispanic participants with established ASCVD and elevated Lp(a), addressing the underrepresentation of these populations in the main HORIZON trial [6].

7.5 Effect on LDL cholesterol

Pelacarsen reduces Lp(a)-associated cholesterol, which is a component of the LDL cholesterol value measured by standard clinical assays (Friedewald calculation and direct LDL-c assays do not distinguish Lp(a)-cholesterol from true LDL-cholesterol). In the Phase 2b trial, pelacarsen reduced measured LDL cholesterol by approximately 15 to 25 percent at the highest doses; however, the "corrected" LDL cholesterol (total LDL-c minus Lp(a)-cholesterol) was not significantly changed, indicating that the LDL-c reduction reflects removal of the Lp(a)-cholesterol component rather than an effect on the LDL receptor pathway [15]. This finding has implications for clinical interpretation: apparent LDL-c reductions in pelacarsen-treated patients do not represent the same mechanism as statin-mediated LDL-c lowering.

8. Sourcing and Quality Verification

Pelacarsen is an investigational compound that has not received marketing authorization from any regulatory agency as of the monograph preparation date. The compound is not commercially available as a pharmaceutical product. Access is limited to participants in registered clinical trials conducted under Novartis sponsorship [2, 6].

Research-grade pelacarsen or structurally related GalNAc-conjugated antisense oligonucleotides targeting LPA mRNA are available from specialized oligonucleotide synthesis companies (e.g., MedChemExpress, Selleckchem) for in vitro and preclinical research applications. These research-grade preparations are not manufactured under cGMP conditions and are not suitable for human administration.

Investigators acquiring research-grade material should confirm:

- Oligonucleotide identity by mass spectrometry (expected molecular weight 8636.36 g/mol for the full conjugate)
- Sequence integrity by sequencing or high-resolution mass spectrometry
- Purity by anion-exchange HPLC or capillary electrophoresis (target greater than 90 percent full-length product)
- GalNAc3 conjugation integrity by LC-MS or MALDI-TOF
- Endotoxin content (for any in vivo application)
- Sterility (for any in vivo application)

The research-grade antisense oligonucleotide market is less established than the small-molecule research chemical market; lot-to-lot variability in oligonucleotide synthesis quality is a recognized concern, and independent analytical confirmation of vendor certificates of analysis is appropriate for mechanism-of-action or dose-response studies.

9. Reconstitution and Handling

Pelacarsen for clinical use is supplied as a ready-to-use solution for subcutaneous injection in a prefilled syringe or autoinjector, requiring no reconstitution. The pharmaceutical formulation is a clear to slightly opalescent, colorless to pale yellow aqueous solution at a concentration suitable for delivery of 80 mg in a single injection volume [6].

Storage conditions: Refrigerated storage at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) in the original carton to protect from light. If necessary, the prefilled syringe or autoinjector may be stored at room temperature (up to 25 degrees Celsius, 77 degrees Fahrenheit) for a maximum of 14 days, after which unused product must be discarded. The compound should not be frozen. The product should not be used beyond the labeled expiration date [6].

Administration: Subcutaneous injection into the abdomen, thigh, or upper arm. Injection sites should be rotated to minimize cumulative injection site reactions. The injection should be allowed to reach room temperature for approximately 30 minutes before administration to reduce injection-site discomfort.

Research-grade material: Lyophilized or solution preparations of research-grade pelacarsen or related ASOs should be stored at minus 20 degrees Celsius for long-term storage. Reconstitution of lyophilized material in nuclease-free water or phosphate-buffered saline to the desired concentration is standard. Aliquoting to avoid freeze-thaw cycles is recommended; phosphorothioate oligonucleotides are generally stable through at least 5 freeze-thaw cycles without measurable degradation, but single-use aliquots are best practice for quantitative studies. Working solutions should be prepared in nuclease-free conditions and used within 24 hours if not stored at minus 20 degrees Celsius.

10. Stack Interactions and Combinations

Pelacarsen does not interact with cytochrome P450 enzymes, transporters, or other conventional drug-metabolizing pathways, and the risk of pharmacokinetic drug-drug interactions is correspondingly low. The following interaction considerations are relevant for clinical and research applications:

Lipid-lowering therapy: Pelacarsen is administered on a background of optimized standard-of-care lipid-lowering therapy in the Phase 3 trials, including statins, ezetimibe, and PCSK9 inhibitors. No pharmacokinetic interactions between pelacarsen and these agents have been identified. The pharmacodynamic interaction is additive: statins and PCSK9 inhibitors reduce LDL cholesterol through the LDL receptor pathway, while pelacarsen reduces Lp(a) through inhibition of apo(a) synthesis. The combination addresses complementary components of atherogenic lipoprotein burden [1, 6].

Anticoagulant and antiplatelet agents: Pelacarsen is co-administered with antiplatelet therapy (aspirin, clopidogrel, ticagrelor) in the Phase 3 trials. The phosphorothioate backbone of ASOs has a theoretical potential for anticoagulant-like effects at very high concentrations through binding to thrombin and other coagulation factors; this has not been observed at the clinical doses of pelacarsen. No dose adjustment of anticoagulant or antiplatelet therapy is anticipated [3].

Other Lp(a)-lowering agents: The combination of pelacarsen with other Lp(a)-lowering agents (olpasiran, lepodisiran, muvalaplin) has not been studied in clinical trials. A Novartis-sponsored trial (NCT06813911) evaluates the combination of pelacarsen with inclisiran (a PCSK9-targeting siRNA). The combination of an LPA-targeting ASO with an LPA-targeting siRNA would be mechanistically redundant; the combination of pelacarsen with muvalaplin (which inhibits Lp(a) particle assembly rather than apo(a) synthesis) is a theoretically additive combination that has not been studied [6].

Hepatotoxic agents: Although pelacarsen has not demonstrated clinically significant hepatotoxicity, the hepatocyte-directed mechanism of action and hepatic accumulation warrant monitoring of liver function when co-administered with

known hepatotoxic agents. Concurrent use with other hepatocyte-targeted oligonucleotide therapeutics (e.g., inclisiran, givosiran, lumasiran) represents a theoretical concern for cumulative hepatocyte oligonucleotide burden, though no clinical evidence of additive hepatotoxicity has been reported [3].

Vaccines and immunomodulators: Phosphorothioate oligonucleotides have inherent immunostimulatory properties through engagement of Toll-like receptors (TLR9 for CpG-containing sequences). The 2'-MOE modifications of pelacarsen substantially reduce this immunostimulatory potential. No clinically significant interactions with vaccines or immunomodulatory therapies have been identified in clinical trials [4].

11. Adverse Events and Safety Signal

11.1 Common adverse events

The principal adverse events observed in Phase 1 and Phase 2 trials of pelacarsen are:

- Injection site reactions (erythema, pain, induration, pruritus at the injection site): reported in approximately 27 percent of the highest-dose group in the Phase 2b trial; predominantly mild (Grade 1) and self-limiting, resolving within 1 to 3 days without intervention [1]
- Influenza-like symptoms (myalgia, fatigue, headache, chills): reported in a minority of participants, predominantly in the first 24 to 48 hours after injection, consistent with the mild pro-inflammatory properties of phosphorothioate oligonucleotides [1, 13]
- Headache: reported in a small percentage of participants, at rates similar to placebo [1]

11.2 Hepatic safety

Pelacarsen has not produced clinically significant elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in Phase 1 or Phase 2 trials. Hepatic steatosis, a theoretical concern for therapies that reduce hepatic lipoprotein secretion, has not been observed with pelacarsen, consistent with the specificity of the compound for apo(a) (which does not carry triglyceride) rather than for apoB-100 (which is essential for VLDL and LDL secretion) [1, 3].

11.3 Hematological safety

Thrombocytopenia is a recognized class effect of phosphorothioate antisense oligonucleotides at high doses, attributed to platelet-oligonucleotide interactions. Pelacarsen at clinical doses (80 mg monthly) has not produced clinically relevant platelet reductions in Phase 1 or Phase 2 trials [1, 10].

11.4 Renal safety

Accumulation of phosphorothioate oligonucleotides in renal proximal tubular epithelium is a recognized class feature, with potential for tubular toxicity at high chronic doses. Pelacarsen at clinical doses has not produced clinically significant changes in serum creatinine, estimated glomerular filtration rate, or urinary biomarkers of tubular injury in Phase 1 or Phase 2 trials [1, 3].

11.5 Cardiovascular safety

No ECG abnormalities, QT prolongation, or arrhythmic events have been attributed to pelacarsen in Phase 1 or Phase 2 trials. The dedicated hepatic impairment PK study reported no concerning ECG changes [10].

11.6 Immunogenicity

Antisense oligonucleotides are not proteins and do not typically elicit anti-drug antibody responses. CpG-mediated TLR9 activation is minimized by 2'-MOE modification. No clinically significant immunogenic responses have been reported with pelacarsen [3, 4].

11.7 Pregnancy and lactation

There are no human pregnancy or lactation data for pelacarsen. The compound is classified as an investigational drug and is contraindicated in pregnancy in the clinical trial protocols. Preclinical reproductive toxicology data are not publicly available. Given the hepatocyte-directed mechanism and the large molecular weight (8.6 kDa), placental transfer and excretion in breast milk are expected to be minimal, though this has not been confirmed [6].

11.8 Long-term safety

Long-term safety data beyond the Phase 2 trial duration (6 to 12 months) are not yet available from controlled studies. The Lp(a)HORIZON trial, with a minimum follow-up of 2.5 years and a mean follow-up expected to exceed 3 years, will provide the definitive long-term safety database. Class experience with other marketed GalNAc-

conjugated ASOs (inotersen for transthyretin amyloidosis) provides supportive evidence for long-term tolerability of the ASO platform, though each compound has a unique toxicity profile [6, 14].

12. Comparative Assessment

This section presents a structured comparative assessment of five Lp(a)-lowering agents against pelacarsen, evaluated against five competency standards: novelty, effect size (Lp(a) reduction), promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected as the principal agents with substantive clinical or late-preclinical data for Lp(a) lowering: olpasiran, zerlasiran, lepodisiran, and muvalaplin (all targeting Lp(a) through distinct mechanisms) and niacin (the historical reference agent).

12.1 Olpasiran (AMG 890)

Mechanism: GalNAc-conjugated small interfering RNA (siRNA) targeting LPA mRNA, triggering RNA-induced silencing complex (RISC)-mediated degradation of the mRNA in hepatocytes. The siRNA mechanism operates through the RISC pathway rather than the RNase H1 pathway used by pelacarsen [18].

Developer: Amgen.

Development stage: Phase 3 (OCEAN(a)-Outcomes trial, cardiovascular outcomes).

Lp(a) reduction: In the Phase 2 OCEAN(a)-DOSE trial, olpasiran produced placebo-adjusted Lp(a) reductions of 70.5 percent (10 mg every 12 weeks) to 101.1 percent (225 mg every 12 weeks), with the highest doses achieving near-complete suppression of Lp(a) [18].

Dosing: Subcutaneous injection every 12 to 24 weeks (quarterly to semi-annual dosing), a substantially less frequent regimen than pelacarsen monthly.

Novelty: High. The siRNA mechanism is distinct from the ASO mechanism and offers potentially more potent and sustained target knockdown through RISC-mediated catalytic mRNA degradation.

Effect size: Olpasiran achieves greater maximal Lp(a) reduction (greater than 95 percent at higher doses) than pelacarsen (approximately 80 percent at the Phase 3 dose). The clinical significance of the incremental reduction beyond 80 percent is

unknown pending outcomes data from both Phase 3 trials.

Promising potential: High. Phase 3 cardiovascular outcomes trial (OCEAN(a)-Outcomes) is ongoing in parallel with Lp(a)HORIZON.

Side-effect profile: Mild injection site reactions, consistent with the GalNAc-conjugated oligonucleotide class. No clinically significant hepatic, renal, or hematological toxicity in Phase 2 [18].

Overall validation: High. Extensive Phase 2 data with robust dose-response and a Phase 3 outcomes trial in progress.

Comparison to pelacarsen: Olpasiran offers greater maximal Lp(a) reduction and less frequent dosing but is at a similar stage of clinical development. Pelacarsen has the advantage of a larger Phase 3 trial (8,323 versus approximately 7,000 patients in OCEAN(a)-Outcomes) and a longer clinical development history. The head-to-head comparison will depend on cardiovascular outcomes data from both trials.

12.2 Zerlasiran (SLN360)

Mechanism: GalNAc-conjugated 19-mer siRNA targeting LPA mRNA, operating through the same RISC-mediated pathway as olpasiran [19].

Developer: Silence Therapeutics.

Development stage: Phase 2 completed (ALPACAR-360); Phase 3 planning assumed.

Lp(a) reduction: In the Phase 2 ALPACAR-360 trial, zerlasiran at 300 to 450 mg every 16 to 24 weeks produced time-averaged Lp(a) reductions of 82.8 to 85.6 percent, with peak reductions up to 98 percent [19].

Dosing: Subcutaneous injection every 16 to 24 weeks.

Novelty: Moderate. The mechanism is similar to olpasiran (siRNA targeting LPA mRNA); the structural chemistry differs.

Effect size: Peak reductions comparable to olpasiran; time-averaged reductions of 83 to 86 percent, modestly greater than pelacarsen.

Promising potential: Moderate. Phase 2 completed with positive results; Phase 3 cardiovascular outcomes trial not yet initiated, placing zerlasiran behind pelacarsen and olpasiran in the development timeline.

Side-effect profile: Mild, self-limiting injection site reactions. A transient, dose-dependent elevation in C-reactive protein was observed in Phase 2, a finding not reported with pelacarsen or olpasiran and of uncertain clinical significance [19].

Overall validation: Moderate. Positive Phase 2 data but no Phase 3 outcomes trial initiated.

Comparison to pelacarsen: Zerlasiran offers similar or modestly greater Lp(a) reduction with less frequent dosing. Pelacarsen is substantially further advanced in clinical development, with an 8,323-patient Phase 3 outcomes trial nearing completion.

12.3 Lepodisiran (LY3819469)

Mechanism: GalNAc-conjugated siRNA targeting LPA mRNA, RISC-mediated degradation [20].

Developer: Eli Lilly.

Development stage: Phase 3 (ACCLAIM-Lp(a) trial, cardiovascular outcomes; uniquely includes a primary prevention arm).

Lp(a) reduction: In the Phase 2 ALPACA trial, a single 400 mg dose produced a placebo-adjusted time-averaged Lp(a) reduction of 93.9 percent at day 180, with reduction persisting above 90 percent at 360 days after a single injection [20].

Dosing: Ultra-infrequent dosing: potentially once or twice yearly based on Phase 2 data, the least frequent of any Lp(a)-lowering agent in development.

Novelty: Moderate. The siRNA mechanism is shared with olpasiran and zerlasiran; the distinguishing feature is the potency enabling once- or twice-yearly dosing.

Effect size: The highest among the comparators; single-dose Lp(a) reduction exceeding 90 percent sustained for up to 12 months.

Promising potential: High. Phase 3 outcomes trial in progress, with the added distinction of including a primary prevention arm (patients with elevated Lp(a) but without established ASCVD), addressing a population not studied in the pelacarsen or olpasiran Phase 3 trials.

Side-effect profile: Mild, dose-dependent injection site reactions. No serious safety signals in Phase 2 [20].

Overall validation: Moderate to high. Positive Phase 2 data with distinctive ultra-long duration of effect; Phase 3 outcomes trial in progress.

Comparison to pelacarsen: Lepodisiran offers greater Lp(a) reduction, longer duration of effect, and less frequent dosing than pelacarsen. Pelacarsen has the advantage of a larger and more mature Phase 3 program. The primary prevention arm of the ACCLAIM-Lp(a) trial addresses a clinical question not studied in the pelacarsen program.

12.4 Muvalaplin (LY3473329)

Mechanism: Oral small-molecule inhibitor that selectively blocks the non-covalent interaction between the kringle IV domain of apo(a) and apolipoprotein B-100, thereby preventing Lp(a) particle assembly in the liver. This mechanism is fundamentally distinct from the mRNA-targeting approaches of pelacarsen, olpasiran, zerlasiran, and lepodisiran [21].

Developer: Eli Lilly.

Development stage: Phase 2 completed (KRAKEN trial); Phase 3 cardiovascular outcomes trial planned.

Lp(a) reduction: In the Phase 2 KRAKEN trial, muvalaplin at 10 to 240 mg daily produced Lp(a) reductions of 47.6 to 85.8 percent (by intact Lp(a) assay) and 40.4 to 70 percent (by apo(a)-based assay) [21].

Dosing: Oral, once daily. The oral route is the defining advantage of muvalaplin relative to all injectable competitors.

Novelty: High. The small-molecule mechanism targeting Lp(a) particle assembly (rather than mRNA) is mechanistically distinct from all other agents in the comparator panel.

Effect size: Moderate to high. Peak reductions of approximately 65 to 86 percent (assay-dependent), somewhat lower than the siRNA agents but comparable to pelacarsen.

Promising potential: Moderate to high. The oral route of administration is a substantial practical advantage for chronic cardiovascular risk management and patient adherence. Phase 3 outcomes trial not yet initiated.

Side-effect profile: Generally well tolerated; adverse event rates similar to placebo. A modest reduction in plasminogen activity (approximately 14 percent) was observed, reflecting the structural homology between apo(a) and plasminogen; the clinical significance is uncertain but warrants monitoring [21].

Overall validation: Moderate. Positive Phase 2 data with a novel mechanism and oral administration; no Phase 3 outcomes data.

Comparison to pelacarsen: Muvalaplin offers oral administration, a transformative practical advantage for chronic therapy. Pelacarsen offers somewhat greater Lp(a) reduction and is substantially further advanced in clinical development. The potential for combination therapy (muvalaplin inhibiting Lp(a) particle assembly plus pelacarsen inhibiting apo(a) synthesis) is mechanistically rational but unstudied.

12.5 Niacin (nicotinic acid)

Mechanism: Niacin reduces Lp(a) by approximately 20 to 30 percent through an incompletely characterized mechanism, likely involving reduced hepatic apo(a) secretion. Niacin also reduces LDL cholesterol, raises HDL cholesterol, and reduces triglycerides through multiple hepatic metabolic effects [11, 12].

Development stage: Marketed (generic, multiple formulations). Lp(a) lowering is not a registered indication.

Lp(a) reduction: Approximately 20 to 30 percent at extended-release doses of 1,500 to 2,000 mg daily, substantially less than all targeted Lp(a)-lowering agents.

Dosing: Oral, once or twice daily. Extended-release formulation (Niaspan, generics) at 1,500 to 2,000 mg daily.

Novelty: Low. Niacin has been available for decades and its Lp(a)-lowering effect is a secondary pharmacological property.

Effect size: Low. The 20 to 30 percent Lp(a) reduction is insufficient to achieve clinically meaningful absolute Lp(a) reductions in most patients with elevated Lp(a) concentrations. The AIM-HIGH trial and HPS2-THRIVE trial demonstrated no incremental cardiovascular benefit when niacin was added to statin therapy, though these trials were not designed to evaluate Lp(a)-specific outcomes [11, 12].

Promising potential: Low for Lp(a)-specific therapy. Niacin has been largely abandoned in clinical practice owing to the negative outcomes trials, the unfavorable side-effect profile, and the availability of more effective and better-tolerated alternatives.

Side-effect profile: Flushing (prostaglandin-mediated cutaneous vasodilation) in 60 to 80 percent of patients, hepatotoxicity at higher doses, glucose intolerance, hyperuricemia, and gastrointestinal discomfort. The flushing is the principal tolerability-limiting adverse event and has substantially reduced patient adherence and clinical utilization [11].

Overall validation: Low for Lp(a)-specific therapy. High for historical importance as the first agent recognized to reduce Lp(a) concentrations.

Comparison to pelacarsen: Niacin offers substantially less Lp(a) reduction (20 to 30 percent versus approximately 80 percent), a substantially worse tolerability profile, and negative cardiovascular outcomes trial data. Pelacarsen is superior on every comparator standard except availability (niacin is marketed and widely accessible; pelacarsen is investigational).

12.6 Comparator summary

The five agents occupy distinct positions in the Lp(a)-lowering therapeutic landscape. **Olpasiran** is the closest competitor to pelacarsen, offering greater maximal Lp(a) reduction and less frequent dosing through the siRNA mechanism, with a Phase 3 outcomes trial running in parallel. **Lepodisiran** offers the most potent and sustained effect, with a unique ultra-infrequent dosing schedule and a Phase 3 program that includes primary prevention. **Zerlasiran** is a third siRNA option with positive Phase 2 data but less advanced development. **Muvalaplin** represents the most mechanistically distinct approach with oral administration, a transformative practical advantage, but is earlier in development. **Niacin** is the historical reference with inadequate efficacy and unfavorable tolerability.

Pelacarsen occupies the most clinically mature position among the targeted agents: it has the largest Phase 3 outcomes trial (8,323 patients), the longest clinical development history, the most extensive pharmacokinetic and safety database, and the most imminent anticipated outcomes readout (2026). Its principal competitive disadvantage is the lower maximal Lp(a) reduction relative to the siRNA agents and the monthly subcutaneous dosing frequency relative to the quarterly or annual dosing of the siRNAs. Whether the incremental Lp(a) reduction achieved by siRNAs translates to incremental cardiovascular benefit is unknown and will be resolved only by comparison of the outcomes trial results.

The field of Lp(a)-lowering therapeutics is unprecedented in cardiovascular pharmacology: within a single decade, the therapeutic landscape has advanced from no effective pharmacotherapy to five distinct agents in Phase 2 or Phase 3 development targeting a single lipoprotein particle through four distinct molecular mechanisms (ASO, siRNA, small-molecule assembly inhibitor, and niacin). The outcomes of the ongoing Phase 3 trials will determine whether Lp(a) lowering achieves the cardiovascular risk reduction predicted by genetic epidemiology and whether pelacarsen, as the first targeted agent to complete a large outcomes trial, establishes the therapeutic paradigm.

13. References

1. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. *N Engl J Med*. 2020;382(3):244-255.
2. Novartis press release. Novartis exercises option to license pelacarsen (TQJ230) from Ionis Pharmaceuticals for \$150 million. February 2019.
3. Crooke ST, Baker BF, Crooke RM, Liang XH. Antisense technology: an overview and prospectus. *Nat Rev Drug Discov*. 2021;20(6):427-453.
4. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. *Annu Rev Pharmacol Toxicol*. 2010;50:259-293.
5. Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. *Nucleic Acids Res*. 2014;42(13):8796-8807.
6. Novartis. Lp(a)HORIZON: a multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on major cardiovascular events. *ClinicalTrials.gov* identifier: NCT04023552.
7. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J*. 2010;31(23):2844-2853.
8. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. *Eur Heart J*. 2022;43(39):3925-3946.
9. Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. *JAMA Cardiol*. 2018;3(7):619-627.
10. Yan JH, Bautista E, Li Y, et al. Pharmacokinetics and safety of pelacarsen, a GalNAc3-conjugated antisense oligonucleotide targeting apo(a), in participants with mild hepatic impairment. *Clin Transl Sci*. 2025;18(6):e70344.

11. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med*. 2011;365(24):2255-2267.
12. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. *N Engl J Med*. 2014;371(3):203-212.
13. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. *Lancet*. 2015;386(10002):1472-1483.
14. O'Donoghue ML, Rosenson RS, Gencer B, et al. Design and rationale of the Lp(a)HORIZON trial: a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events. *Am Heart J*. 2025;283:125-135.
15. Bittner VA, Szarek M, Aylward PE, et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. *J Am Coll Cardiol*. 2022;79(11):1035-1046.
16. Ionis Pharmaceuticals. A study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of pelacarsen (ISIS 681257) in healthy Japanese participants. *ClinicalTrials.gov* identifier: NCT05337878.
17. Lp(a)FRONTIERS APHERESIS investigators. A multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the rate of weekly lipoprotein apheresis sessions. *ClinicalTrials.gov* identifier: NCT05305664.
18. O'Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. *N Engl J Med*. 2022;387(20):1855-1864.
19. Silence Therapeutics. ALPACAR-360: phase 2 study of zerlasiran (SLN360) in participants with elevated lipoprotein(a). Results presented at American Heart Association Scientific Sessions 2023.
20. Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. *JAMA*. 2022;327(17):1679-1687.

21. Nicholls SJ, Nissen SE, Fleming D, et al. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial. JAMA. 2023;330(2):131-141.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Pelacarsen is an investigational compound that has not received marketing authorization from any regulatory agency. The compound is accessible only through registered clinical trials. Investigators should consult their institutional review board and regulatory authority before any research application. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly.